Canaccord Genuity set a $75.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Saturday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

ANIP has been the subject of several other reports. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 target price for the company in a report on Tuesday, November 7th. ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, November 25th. TheStreet upgraded shares of ANI Pharmaceuticals from a c+ rating to a b rating in a report on Thursday, November 16th. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 18th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $70.50.

ANI Pharmaceuticals (ANIP) traded up $2.14 during mid-day trading on Friday, hitting $69.43. 121,491 shares of the stock traded hands, compared to its average volume of 165,790. ANI Pharmaceuticals has a 1 year low of $42.23 and a 1 year high of $74.70. The stock has a market capitalization of $809.07, a price-to-earnings ratio of 20.73 and a beta of 2.91. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to analyst estimates of $48.12 million. During the same period last year, the business earned $1.09 earnings per share. The business’s revenue was up 25.0% on a year-over-year basis. analysts forecast that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. raised its holdings in ANI Pharmaceuticals by 67.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 9,493 shares of the specialty pharmaceutical company’s stock worth $444,000 after acquiring an additional 3,837 shares during the last quarter. Vanguard Group Inc. raised its holdings in ANI Pharmaceuticals by 8.1% in the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after acquiring an additional 35,722 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in ANI Pharmaceuticals by 9.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 42,428 shares of the specialty pharmaceutical company’s stock worth $1,986,000 after acquiring an additional 3,522 shares during the last quarter. Intrust Bank NA raised its holdings in ANI Pharmaceuticals by 11.8% in the 2nd quarter. Intrust Bank NA now owns 5,051 shares of the specialty pharmaceutical company’s stock worth $236,000 after acquiring an additional 535 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in ANI Pharmaceuticals by 26.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 15,020 shares of the specialty pharmaceutical company’s stock worth $703,000 after acquiring an additional 3,183 shares during the last quarter. Institutional investors own 55.05% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ANI Pharmaceuticals (ANIP) Given a $75.00 Price Target by Canaccord Genuity Analysts” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/10/ani-pharmaceuticals-anip-given-a-75-00-price-target-by-canaccord-genuity-analysts.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.